Docteur E. BAUDUIN
ActiveSummary
Docteur E. BAUDUIN has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €626,202 and a net result of €122,579. Equity has been stable since 2019 (±2.2% per year). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 14-12-2005 Normal situation
- Activity
- “La société a pour objet l'exercice de la médecine par le ou les associés…” (deed in French)From the articles, 7 activitiesNo NACE code in the KBO yet
- Financial year end
- 30 June
- Peppol
- Not found in the Peppol Directory
Board and ownership
Board
- Roseline VAN DER MAESENDirector
- BAUDUIN Emmanuel Philippe HenriDirector
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
Annual accounts to 30-06-2025
- Gross margin
- €185,480
- ▲ 5.8%
- Turnover
- ≈ €460,000
- estimated
- Profit
- €122,579
- ▲ 36.1%
- Equity
- €626,202
- ▼ 1.2%
- Total assets
- €760,794
- ▲ 5.6%
Score breakdownraises riskNo registered site in the KBOlowers riskSize: total assets €760,794Equity €626,202 (82.3% of total assets)Liquidity: current ratio 5.02, cash €173,888Show the evidence
Checked score
Score 2025
95
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 61% of micro companies without a NACE code
Financial strength · tick: 2024
Strong
Solvency
100=
equity 82.3% of total assets
Liquidity
74-23
short-term debt 17.6% · cash 22.9%
Profitability
74+11
return on assets 16.1%
Bankruptcy probability within 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: 0.1%▲ +0.1 percentage points vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025highest value
03-2025: < 0.1%▼ -0.1 percentage points vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026lowest value
03-2026: < 0.1%● unchanged vs 02-2026lowest value
04-2026: < 0.1%● unchanged vs 03-2026lowest value
05-2026: < 0.1%● unchanged vs 04-2026lowest value
06-2026: < 0.1%● unchanged vs 05-2026lowest value
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €55,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 5.02 (8.16 in 2024), above the usual 1.5. Short-term debt is 17.6% and cash 22.9% of total assets. 17.7% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 81% of them on solvency, 69% on liquidity, 55% on profitability and 40% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 09-12-2025, 53 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
53 days early
2024
28 days late
2023
11 days early
2022
4 days early
2021
49 days early
2020
26 days early
2019
24 days early
← before the deadline
after the deadline →
tick = median of all Belgian filings
The company filed its last 7 accounts on average 20 days before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 20 January (4 of the last 5 accounts filed within 39 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end03-11-2026 today31-01-2027 deadline
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 09-12-2025 PDF all 20 filings
Turnover
≈ €460,000
Estimated: probably between €310,000 and €720,000
Total assets
€760,794▲ 5.6%
2024 · €720,279
Net result
€122,579▲ 36.1%
2024 · €90,087
Working capital
€539,241▼ 12.8%
2024 · €618,099
Multi-year overview
2019 to 2025, 7 financial yearsOperating result
€176,023
▲ 6.5%
2025
20192025
Net result
€122,579
▲ 36.1%
2025
20192025
Equity
€626,202
▼ 1.2%
2025
20192025
Total assets
€760,794
▲ 5.6%
2025
20192025
Debt
€134,592
▲ 55.3%
2025
20192025
Working capital
€539,241
▼ 12.8%
2025
20192025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line2019202020212022202320242025
Operating result€198,969-€251,534▲ 26.4%€198,271▼ 21.2%€204,876▲ 3.3%€212,738▲ 3.8%€165,308▼ 22.3%€176,023▲ 6.5%
Net result€86,464-€140,288▲ 62.2%€126,382▼ 9.9%€127,080▲ 0.6%€111,726▼ 12.1%€90,087▼ 19.4%€122,579▲ 36.1%
Equity€550,059-€608,347▲ 10.6%€549,730▼ 9.6%€596,810▲ 8.6%€628,536▲ 5.3%€633,623▲ 0.8%€626,202▼ 1.2%
Total assets€570,144-€724,351▲ 27.0%€750,932▲ 3.7%€685,858▼ 8.7%€711,952▲ 3.8%€720,279▲ 1.2%€760,794▲ 5.6%
Debt€20,086-€116,004▲ 478%€201,202▲ 73.4%€89,048▼ 55.7%€83,416▼ 6.3%€86,656▲ 3.9%€134,592▲ 55.3%
Working capital€530,635-€583,209▲ 9.9%€527,239▼ 9.6%€554,801▲ 5.2%€604,815▲ 9.0%€618,099▲ 2.2%€539,241▼ 12.8%
The operating result for 2025 is 6% higher than in 2024. It is a recovery after the fall in 2024.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €760,794
Fixed assets
€87,360 ▲ 449%
Current assets
€673,433 ▼ 4.4%
Equity and liabilities €760,794
Equity
€626,202 ▼ 1.2%
Debt
€134,592 ▲ 55.3%
Debt's share of the balance-sheet total rises from 12.0% to 17.7%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€183,966▲
2024 · €173,607
Cash flow
€130,521▲
2024 · €98,387
Current ratio
5.02▼
2024 · 8.16
Debt to equity
0.21▲
2024 · 0.14
ROE
19.6%▲
2024 · 14.2%
ROA
16.1%▲
2024 · 12.5%
Interest coverage
4.18▲
2024 · 3.48
Debt ≤ 1 year
€134,192▲
2024 · €86,269
Income taxes
€50,431▲
2024 · €37,120
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Investments
| Item | 30-06-2022 | 30-06-2023 | 30-06-2024 | 30-06-2025 |
|---|---|---|---|---|
| Tangible fixed assets | €37,054 | - | - | €79,392 |
| Depreciation and write-downs of the year | €17,536 | €18,147 | €8,299 | €7,942 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €8,880 | €8,654 | €10,983 | €17,536 | €18,147 | €8,299 | €7,942 | ▼ 4.3% |
| Other operating charges640/8 | - | - | - | €1,569 | €3,469 | €1,687 | €1,514 | ▼ 10.3% |
| Gross operating margin9900 | €213,151 | €261,594 | €210,665 | €223,981 | €234,354 | €175,294 | €185,480 | ▲ 5.8% |
| Operating profit (loss)9901 | €198,969 | €251,534 | €198,271 | €204,876 | €212,738 | €165,308 | €176,023 | ▲ 6.5% |
| Financial income75/76B | - | - | - | €26,085 | €13,233 | €11,855 | €41,018 | ▲ 246% |
| Recurring financial income75 | €14,426 | €14,527 | €25,466 | €26,085 | €13,233 | €11,855 | €24,518 | ▲ 107% |
| Non-recurring financial income76B | - | - | - | - | - | - | €16,500 | - |
| Financial charges65/66B | - | - | - | €49,269 | €64,430 | €49,956 | €44,031 | ▼ 11.9% |
| Recurring financial charges65 | €106,792 | €59,982 | €43,408 | €49,269 | €64,430 | €49,956 | €44,031 | ▼ 11.9% |
| Profit (loss) for the period before taxes9903 | €122,353 | €206,078 | €180,330 | €181,692 | €161,541 | €127,207 | €173,010 | ▲ 36.0% |
| Income taxes67/77 | €35,888 | €65,790 | €53,947 | €54,611 | €49,815 | €37,120 | €50,431 | ▲ 35.9% |
| Profit (loss) for the period9904 | €86,464 | €140,288 | €126,382 | €127,080 | €111,726 | €90,087 | €122,579 | ▲ 36.1% |
| Profit (loss) for the period to be appropriated9905 | €86,464 | €140,288 | €126,382 | €127,080 | €111,726 | €90,087 | €122,579 | ▲ 36.1% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €570,144 | €724,351 | €750,932 | €685,858 | €711,952 | €720,279 | €760,794 | ▲ 5.6% |
| Fixed assets21/28 | €31,019 | €29,574 | €22,839 | €42,357 | €24,210 | €15,911 | €87,360 | ▲ 449% |
| Tangible fixed assets22/27 | €31,019 | €29,574 | €22,839 | €42,357 | €24,210 | €15,911 | €87,360 | ▲ 449% |
| Plant, machinery and equipment23 | - | - | - | €1,731 | €1,191 | €672 | €5,074 | ▲ 655% |
| Furniture and vehicles24 | - | - | - | €40,626 | €23,019 | €15,239 | €82,287 | ▲ 440% |
| Current assets29/58 | €539,125 | €694,778 | €728,093 | €643,501 | €687,742 | €704,368 | €673,433 | ▼ 4.4% |
| Amounts receivable within one year40/41 | €155,498 | €168,899 | €151,850 | €191,350 | €153,062 | €114,625 | €158,883 | ▲ 38.6% |
| Other amounts receivable41 | - | - | - | €191,350 | €153,062 | €114,625 | €158,883 | ▲ 38.6% |
| Current investments50/53 | €39,733 | €59,885 | €199,947 | €55,745 | €243,293 | €221,812 | €271,066 | ▲ 22.2% |
| Cash at bank and in hand54/58 | €287,365 | €394,530 | €279,225 | €293,277 | €175,458 | €278,551 | €173,888 | ▼ 37.6% |
| Deferred charges and accrued income490/1 | - | - | - | €103,129 | €115,930 | €89,380 | €69,596 | ▼ 22.1% |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €570,144 | €724,351 | €750,932 | €685,858 | €711,952 | €720,279 | €760,794 | ▲ 5.6% |
| Equity10/15 | €550,059 | €608,347 | €549,730 | €596,810 | €628,536 | €633,623 | €626,202 | ▼ 1.2% |
| Contributions10/11 | €12,500 | - | - | €12,500 | €12,500 | €12,500 | €12,500 | = |
| Reserves13 | €528,695 | €576,695 | €516,695 | €561,695 | €593,395 | €597,395 | €589,395 | ▼ 1.3% |
| Non-distributable reserves130/1 | - | - | - | €14,474 | €14,474 | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €14,474 | €14,474 | - | - | - |
| Tax-exempt reserves132 | - | - | - | €2,221 | €2,221 | €2,221 | €2,221 | = |
| Distributable reserves133 | - | - | - | €545,000 | €576,700 | €595,174 | €587,174 | ▼ 1.3% |
| Profit (loss) carried forward14 | €8,864 | €19,153 | €20,535 | €22,615 | €22,641 | €23,728 | €24,308 | ▲ 2.4% |
| Amounts payable17/49 | €20,086 | €116,004 | €201,202 | €89,048 | €83,416 | €86,656 | €134,592 | ▲ 55.3% |
| Amounts payable after more than one year17 | €11,595 | €4,088 | - | - | - | - | - | - |
| Amounts payable within one year42/48 | €8,490 | €111,569 | €200,854 | €88,701 | €82,927 | €86,269 | €134,192 | ▲ 55.6% |
| Trade debts44 | €231 | €388 | €1,020 | €6,851 | €2,927 | €1,269 | €494 | ▼ 61.0% |
| Suppliers440/4 | - | - | - | €6,851 | €2,927 | €1,269 | €494 | ▼ 61.0% |
| Taxes, remuneration and social security45 | - | - | - | €1,850 | - | - | €946 | - |
| Taxes450/3 | - | - | - | €1,850 | - | - | €946 | - |
| Other amounts payable47/48 | - | - | - | €80,000 | €80,000 | €85,000 | €132,752 | ▲ 56.2% |
| Accrued charges and deferred income492/3 | - | - | - | €348 | €490 | €387 | €400 | ▲ 3.2% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €86,464 | €140,288 | €126,382 | €127,080 | €111,726 | €90,087 | €122,579 | ▲ 36.1% |
| + Depreciation and write-downs630 | €8,880 | €8,654 | €10,983 | €17,536 | €18,147 | €8,299 | €7,942 | ▼ 4.3% |
| Operating cash flow (approximation) | €95,344 | €148,942 | €137,365 | €144,616 | €129,872 | €98,387 | €130,521 | ▲ 32.7% |
| Investment in fixed assets (approximation) | - | -€7,208 | -€4,248 | -€37,054 | €0 | €0 | -€79,392 | - |
| Change in cash | - | €107,165 | -€115,305 | €14,053 | -€117,820 | €103,094 | -€104,664 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 20,136 companies had the same profile as Docteur E. BAUDUIN has now. Two years later, 95.0% were still going and 0.2% had gone bankrupt.
- Small
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
95.0%
was still going
4.7%
stopped otherwise
0.2%
went bankrupt
That fits the bankruptcy probability of Docteur E. BAUDUIN itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,136 companies, not a prediction for Docteur E. BAUDUIN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 20 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-06-2025 | micro format | 09-12-2025 | 2025-00578092 | |
| 30-06-2024 | micro format | 28-02-2025 | 2025-00040951 | |
| 30-06-2023 | micro format | 20-01-2024 | 2024-00004032 | |
| 30-06-2022 | micro format | 27-01-2023 | 2023-00006170 | |
| 30-06-2021 | micro format | 13-12-2021 | 2021-79800389 | |
| 30-06-2020 | micro format | 05-01-2021 | 2021-00100481 | |
| 30-06-2019 | micro format | 07-01-2020 | 2020-00300041 | |
| 30-06-2018 | micro format | 14-12-2018 | 2018-74200317 | |
| 30-06-2017 | micro format | 05-01-2018 | 2018-00200482 | |
| 30-06-2016 | full format | 22-12-2016 | 2016-70800601 |
Board & ownership
Directors
Directors
2 directors, last change in 2021
Roseline VAN DER MAESEN
Current
Director (not named in the articles) · appointed in the act of 08-11-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 09-12-2025
BAUDUIN Emmanuel Philippe Henri
Current
Director (not named in the articles) · in office according to the act of 24-11-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 09-12-2025
Owners and capital
Capital transactions
Capital over time
- 24-11-2023 Converted to unavailable equity
Mandate history
2 people, 2 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Roseline VAN DER MAESEN |
|
| BAUDUIN Emmanuel Philippe Henri |
|
Articles of association
Board and representation
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Portée aux frais généraux indépendamment frais représentation voyages déplacements, assemblée générale décide gratuité ou non”
Capital, shares and profit
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- “100, Article 5”
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Moitié cédant,moitié acquéreurs proportionnellement nombre actions acquises,même en cas refus agrément héritier/légataire, tous cas cessions…”
Articles of association, deed of 24-11-2023 (in French)
Network & group
Docteur E. BAUDUIN shares no director with another company.
Connections & network
2 current directorsThe network starts from the directors of Docteur E. BAUDUIN. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2025
2024
20-01
micro format · 11 days before the deadline
2023
24-11
Gazette deed
Reappointments: BAUDUIN Emmanuel Philippe Henri (director) and Van der Maesen Roseline Marion Suzanne Juliette Ghislaine (director)Amendment of the articles · Capital conversion · Reserve release10 points ▸
Gazette deed
Reappointments: BAUDUIN Emmanuel Philippe Henri (director) and Van der Maesen Roseline Marion Suzanne Juliette Ghislaine (director)
Amendment of the articles · Capital conversion · Reserve release10 points ▸
- Amendment of the articles, mentioned 2 times in the deed
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Reserve release, “supprimer compte de capitaux propres statutairement indisponible, fonds disponibles pour distribution” (deed in French)
- Director reappointment, BAUDUIN Emmanuel Philippe Henri (director (not named in the articles))
- Director reappointment, Van der Maesen Roseline Marion Suzanne Juliette Ghislaine (director (not named in the articles))
- Registered office clause, “4000 Liège,avenue des Ormes,40” (deed in French)
- Other provision, “site internet et adresse électronique” (deed in French)
- Power of attorney
- Director discharge, BAUDUIN Emmanuel Philippe Henri
- Director discharge, Van der Maesen Roseline Marion Suzanne Juliette Ghislaine
08-11
Gazette deed
Appointment: Roseline VAN DER MAESEN (director)3 points ▸
Gazette deed
Appointment: Roseline VAN DER MAESEN (director)
3 points ▸
- Director appointment, Roseline VAN DER MAESEN (director)
- Other provision, “administrateur, acceptation et conformité du mandat” (deed in French)
- General meeting, 04-01-2021
27-01
micro format · 4 days before the deadline
2022
30-06
Financial
Liquidity doublescurrent ratio 7.25
The current ratio rises from 3.62 to 7.25. Short-term debt falls from €200,854 to €88,701.
2021
2020
30-06
Financial
Highest result from 2019 to 2025net €140,288 ▲62.2%
The operating result of €251,534 and the net result of €140,288 are both a record.
07-01
micro format · 24 days before the deadline
2018
14-12
micro format · 48 days before the deadline
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
Docteur E. BAUDUIN in French
Enterprise number
0877.904.339
LEI code
549300TKXBC1LH980F25
live in the LEI register
Legal form
Private limited company
Status
Active, normale toestand
Founded
14-12-2005
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 24-11-2023 (in French)Registered office and establishments
Registered office
Avenue des Ormes 40, 4000 Liège, Belgium
Activities
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 24-11-2023 (in French)
“La société a pour objet l'exercice de la médecine par le ou les associés qui la composent, lesquels sont exclusivement des médecins inscrits…”
7 activities
- La société a pour objet l'exercice de la médecine par le ou les associés qui la composent, lesquels sont exclusivement des médecins inscrits au tableau de l'ordre des médecins ou des sociétés de médecins à personnalité juridique dont les statuts ont été approuvés par le Conseil de l'Ordre des Médecins.
- La médecine est exercée au nom et pour le compte de la société.
- En cas de pluralité d'associés, ceux-ci mettent en commun au sein de la société la partie de leur activité médicale relative à leur spécialité.
- Les honoraires sont perçus par et pour la société.
- L'objet social ne pourra être poursuivi que dans le respect des prescriptions d'ordre déontologique, notamment celles relatives au libre choix du médecin par le patient, à l'indépendance diagnostique et thérapeutique du médecin, au respect du secret médical, à la dignité et à l'indépendance professionnelle du praticien.
- Dans le cadre de cet objet, la société peut accomplir toute opération civile, mobilière ou immobilière.
- La société s'interdit toute exploitation commerciale de la médecine, toute forme de collusion directe ou indirecte, de dichotomie ou de surconsommation.
Invoicing and payment
VAT number
BE 0877.904.339
Financial year and general meeting
Accounts at the NBBFinancial year end
30-06
Sites & property
Location
Buildings and parcels at the address
Ground area
460 m²
Building footprint
148 m²
Building volume
1,457 m³
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 62078A0431/00S015 | Wallonia | 460 m² | 1 · 148 m² | 13.7 m · 3 |